(603520)"Zhejiang Starry Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 603520 · · 13 pages · Chinese
Summary by 6ix AI
The report confirms the accuracy and completeness of the financial information presented, with the board of directors taking legal responsibility for its content. It highlights significant changes in revenue and profit, attributing growth to increased market demand for core products and improved cost management. The report also includes details on shareholder information and the company's financial position as of the end of the reporting period.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Zhejiang Starry Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang Starry Pharmaceutical
- (603520)"Zhejiang Starry Pharmaceutical Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance and Cash Dividend Briefing
- Announcement on Implementation of Dividend Distribution for the First Half of 2026
- Announcement on Resolutions of the 2nd Meeting of the 6th Board of Directors
- Announcement on Results of Shareholding Reduction by the Actual Controller and Completion of Internal Share Transfer Among Persons Acting in Concert
- Announcement on Release of Pledge over Shares Held by the Controlling Shareholder
Follow Zhejiang Starry Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Starry Pharmaceutical